The polypeptide vaccine designed and synthesized based on VSIG3 activates specific cytotoxic T lymphocytes (CTLs) to kill tumor cells and improve the survival rate of gastric cancer patients (10). This evidence concerns the gene IGSF11 and neoplasm.